Xenon Pharmaceuticals Inc.
XENE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2,471 | $2,640 | $3,073 |
| - Cash | $105 | $135 | $117 | $143 |
| + Debt | $7 | $9 | $9 | $9 |
| Enterprise Value | – | $2,345 | $2,532 | $2,939 |
| Revenue | $0 | $0 | $8 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$77 | -$1 | $8 | $0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$90 | -$94 | -$72 | -$77 |
| % Margin | – | – | -961.1% | – |
| Net Income | -$91 | -$85 | -$65 | -$66 |
| % Margin | – | – | -867.3% | – |
| EPS Diluted | -1.15 | -1.07 | -0.83 | -0.84 |
| % Growth | -7.5% | -28.9% | 1.2% | – |
| Operating Cash Flow | -$72 | -$64 | -$62 | -$54 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$72 | -$64 | -$62 | -$55 |